Primaquine diphosphate
Based on 6 publication(s) in Google Scholar
Primaquine diphosphate is a potent antimalaria agent and a potent gametocytocide in falciparum malaria. Primaquine diphosphate prevents relapse in vivax and ovale malaria.
For research use only. We do not sell to patients.
- Purity: 99.28%
- CAS No.: 63-45-6
- Formula: C15H27N3O9P2
- Molecular Weight:455.34
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Breast Cancer Compound Library
HY-L074
-
Antiparasitic Compound library
HY-L082
-
Pediatric Drug Library
HY-L104
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Primaquine diphosphate
MoreAll Parasite Isoforms
More
Biological Activity
|
Plasmodium |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
5 μM
Compound: PQ diphosphate
|
Cytotoxicity against human A2780 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29407988] |
| CAPAN-1 | IC50 |
14.24 μM
Compound: PQ diphosphate
|
Cytotoxicity against human Capan1 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human Capan1 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29407988] |
| HCT-116 | IC50 |
13.99 μM
Compound: PQ
|
Antiproliferative activity against human HCT116 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells measured after 72 hrs by MTT assay
|
[PMID: 31431364] |
| HCT-116 | IC50 |
44.22 μM
Compound: PQ diphosphate
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29407988] |
| HEK293 | IC50 |
10.96 μM
Compound: PQ
|
Antiproliferative activity against human HEK293 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HEK293 cells measured after 72 hrs by MTT assay
|
[PMID: 31431364] |
| HepG2 | IC50 |
>100 μM
Compound: 92125578
|
HARVARD: Cytotoxicity in HepG2 cell line
HARVARD: Cytotoxicity in HepG2 cell line
|
[PMID: 22586124] |
| HepG2 | IC50 |
7.4 μM
Compound: 92125578
|
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
|
[PMID: 22586124] |
| HL-60 | IC50 |
11.36 μM
Compound: PQ diphosphate
|
Cytotoxicity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29407988] |
| K562 | IC50 |
12.04 μM
Compound: PQ diphosphate
|
Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29407988] |
| L6 | IC50 |
27.1 μg/mL
Compound: PQ diphsophate
|
Cytotoxicity against rat L6 cells after 70 hrs by Alamar Blue-based assay
Cytotoxicity against rat L6 cells after 70 hrs by Alamar Blue-based assay
|
[PMID: 29220797] |
| L6 | IC50 |
59.5 μM
Compound: PQ diphosphate
|
Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 70 hrs by Alamar blue assay
Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 70 hrs by Alamar blue assay
|
[PMID: 29407988] |
| MCF7 | IC50 |
5 μM
Compound: PQ diphosphate
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29407988] |
| MCF7 | IC50 |
8.73 μM
Compound: PQ
|
Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay
|
[PMID: 31431364] |
| NCI-H460 | IC50 |
10 μM
Compound: PQ diphosphate
|
Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29407988] |
| NCI-H460 | IC50 |
19.84 μM
Compound: PQ
|
Antiproliferative activity against human H460 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human H460 cells measured after 72 hrs by MTT assay
|
[PMID: 31431364] |
| SW-620 | IC50 |
14 μM
Compound: PQ diphosphate
|
Cytotoxicity against human SW620 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human SW620 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29407988] |
Primaquine diphosphate significantly decreases the cell proliferation of live breast cancer cells, and shows no inhibitory effect on the proliferation of MCF-7 (ER+) and MDA-MB-453 (HER2+) cells. Primaquine diphosphate inhibits the growth, migration, and colony formation of breast cancer cells in vitro[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231, HCC1937 cells, MCF-7, and MDA-MB-453 cells
-
Concentration:5 μM, 10 μM, 20 μM, 40 μM, 80 μM, 100 μM, 120 μM, and 150 μM
-
Incubation Time:24 hours
-
Result:Decreases breast cancer cell viability.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male 6-week-old C57BL/6 albino mice with sporozoite inoculation[2]
-
Dosage:5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, and 25 mg/kg
-
Administration:p.o; daily; for 3 days
-
Result:No blood stage parasitaemia was observed.
Chemical Information
-
CAS No. 63-45-6
-
Appearance Solid
-
Molecular Weight 455.34
-
Formula C15H27N3O9P2
-
Color Orange to reddish brown
-
SMILES
CC(NC1=C2N=CC=CC2=CC(OC)=C1)CCCN.O=P(O)(O)O.O=P(O)(O)O
-
Synonyms
Primaquine phosphate; Primaquine bisphosphate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Network Medicine-Based Strategy Identifies Maprotiline as a Repurposable Drug by Inhibiting PD-L1 Expression via Targeting SPOP in Cancer. [Abstract]2024 Nov 5:e2410285. PMID: 39499771 -
Biomed Pharmacother
As a novel ferroptosis inhibitor, primaquine alleviates I/R-induced retinal neuron death via increasing GSTA1 activity. [Abstract]2026 Feb:195:118973. PMID: 41529513 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
ACS Omega
Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer. [Abstract]2024 Feb 28;9(10):11870-11882. PMID: 38496939 -
-
Ann Transl Med
Integrative identification of the pathogenic role of a novel G6PD missense mutation c.697G>C. [Abstract]2021 Feb;9(3):194. PMID: 33708821
Solvent & Solubility
DMSO : 250 mg/mL (549.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 25 mg/mL (54.90 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.57 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.57 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (109.81 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Portuguese - PT (644 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ashley EA, et al. Primaquine: the risks and the benefits. Malar J. 2014 Nov 3;13:418. [Content Brief]
[2]. Qigui Li, et al. Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections. Malar J. 2014 Apr 14:13:141. [Content Brief]
[3]. Ji-Hyang Kim, et al. Primaquine Inhibits the Endosomal Trafficking and Nuclear Localization of EGFR and Induces the Apoptosis of Breast Cancer Cells by Nuclear EGFR/Stat3-Mediated c-Myc Downregulation. Int J Mol Sci. 2021 Nov 30;22(23):12961. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.1962 mL | 10.9808 mL | 21.9616 mL | 54.9040 mL |
| 5 mM | 0.4392 mL | 2.1962 mL | 4.3923 mL | 10.9808 mL | |
| 10 mM | 0.2196 mL | 1.0981 mL | 2.1962 mL | 5.4904 mL | |
| 15 mM | 0.1464 mL | 0.7321 mL | 1.4641 mL | 3.6603 mL | |
| 20 mM | 0.1098 mL | 0.5490 mL | 1.0981 mL | 2.7452 mL | |
| 25 mM | 0.0878 mL | 0.4392 mL | 0.8785 mL | 2.1962 mL | |
| 30 mM | 0.0732 mL | 0.3660 mL | 0.7321 mL | 1.8301 mL | |
| 40 mM | 0.0549 mL | 0.2745 mL | 0.5490 mL | 1.3726 mL | |
| 50 mM | 0.0439 mL | 0.2196 mL | 0.4392 mL | 1.0981 mL | |
| DMSO | 60 mM | 0.0366 mL | 0.1830 mL | 0.3660 mL | 0.9151 mL |
| 80 mM | 0.0275 mL | 0.1373 mL | 0.2745 mL | 0.6863 mL | |
| 100 mM | 0.0220 mL | 0.1098 mL | 0.2196 mL | 0.5490 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz